---
layout: post
title: "GlaxoSmithKline Intellectual Property Development Ltd. England; Announcement of the Revocation of the Biologics License for BLENREP"
date: 2026-02-05 18:36:05 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-06576
original_published: 2023-03-30 00:00:00 +0000
significance: 8.00
---

# GlaxoSmithKline Intellectual Property Development Ltd. England; Announcement of the Revocation of the Biologics License for BLENREP

**Published:** February 05, 2026 18:36 UTC
**Source:** Federal Register
**Original Published:** March 30, 2023 00:00 UTC
**Document Number:** 2023-06576

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the revocation of the biologics license for BLENREP (belantamab mafodotin-blmf) powder for injection. GlaxoSmithKline Intellectual Property Development Ltd. England (GSK) requested withdrawal (revocation) of the biologics license and has waived its opportunity for a hearing.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/03/30/2023-06576/glaxosmithkline-intellectual-property-development-ltd-england-announcement-of-the-revocation-of-the)
- API: https://www.federalregister.gov/api/v1/documents/2023-06576

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
